Astellas’ Xtandi Gains Another Prostate Cancer Indication in Japan

Astellas’ Xtandi (enzalutamide) has received approval in Japan for treatment of prostate cancer in patients whose cancer has spread from the original tumor.

The approval was based on the results of a phase 3 study of the drug plus androgen deprivation therapy (ADT), which met its primary endpoint of progression-free survival.

The drug was previously approved for treatment of castration-resistant prostate cancer.